Health · Pharma & Biotech · 1 hr ago

FDA approves Sanofi pill for neurological symptoms of Type 3 Gaucher disease

FDA approves Sanofi pill for neurological symptoms of Type 3 Gaucher disease

The FDA approved Sanofi’s Infilbray pill for Type 3 Gaucher disease in the United States for adults and children weighing at least 15 kilograms.

It is the first approved treatment for the disease’s neurological symptoms, which can affect thinking and coordination.

Gaucher disease is an inherited disorder, and in Type 3, fatty molecules build up in the central nervous system.

In a trial, one year of treatment significantly improved neurological symptoms.

The drug carries warnings about suicidal thoughts and behavior, eye lens clouding in children, and possible harm to a developing fetus.

The approval gives Sanofi a potential new revenue source as it prepares for the patent expiration of its top-selling drug, Dupixent; Infilbray’s price has not been announced.

3 sources

Related

What people are saying

Aviva RosenbergCEO and co-founder of the Gaucher Community Alliance
Today’s Infilbray approval marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease.
via BioPharma Dive